Exploration of Natural Chemical Compounds as Novel Post-Pandemic Antiviral Agents: A Review
DOI:
10.29303/jpm.v20i5.9358Published:
2025-07-30Issue:
Vol. 20 No. 5 (2025)Keywords:
Antiviral; Flavonoids; Natural Compounds; Post-Pandemic; Viral ProteaseArticles
Downloads
How to Cite
Downloads
Metrics
Abstract
The COVID-19 pandemic has accelerated the search for effective, safe, and sustainable antiviral agents. One promising approach is the utilization of natural chemical compounds derived from plants, microorganisms, and marine organisms. These compounds, such as flavonoids, alkaloids, terpenoids, and polyphenols, have long been known for their broad biological activities, including antiviral properties. This article aims to explore the potential of natural chemical compounds as new post-pandemic antiviral candidates through a systematic literature review of 28 scientific articles published between 2019 and 2024 from major databases such as PubMed, ScienceDirect, and SpringerLink. The findings indicate that 24 out of 28 reviewed compounds demonstrated significant antiviral activity, with 15 flavonoids targeting viral protease or spike protein through mechanisms like Mpro inhibition, ACE2 interaction, or cytokine modulation. Key challenges include low bioavailability, complexity in compound isolation, and lack of pharmaceutical standardization. However, advanced technological approaches such as nanoformulation, semi-synthetic analogue development, and the use of bio-refinery systems offer potential solutions to enhance the stability and effectiveness of these compounds. This article also highlights the importance of policy support and interdisciplinary collaboration in accelerating the translation of natural compounds from laboratory research to clinical application. The review offers practical implications for pharmaceutical innovation, particularly in biodiversity-rich countries such as Indonesia.
References
World Health Organization, "Coronavirus Dashboard," 2023. [Online]. Available: https://covid19.who.int
D. J. Newman and G. M. Cragg, "Natural products as sources of new drugs," J. Nat. Prod., vol. 83, no. 3, pp. 770–803, 2020, doi: 10.1021/acs.jnatprod.9b01285.
S. Jo, et al., "Inhibitory effects of flavonoids on SARS-CoV-2 main protease," Int. J. Biol. Macromol., vol. 164, pp. 471–479, 2020, doi: 10.1016/j.ijbiomac.2020.07.132.
T. T. Nguyen, et al., "Computational studies of natural compounds," ChemRxiv, 2020, doi: 10.26434/chemrxiv.12029523.
D. Bhowmik, et al., "Herbal antiviral agents and their challenges," Phytomedicine, vol. 85, p. 153343, 2021, doi: 10.1016/j.phymed.2020.153343.
Kementerian Lingkungan Hidup dan Kehutanan Republik Indonesia, "Biodiversitas dan Tanaman Obat di Indonesia," 2022. [Online]. Available: https://www.menlhk.go.id
D. Moher, et al., "Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement," PLoS Med., vol. 6, no. 7, e1000097, 2009, doi: 10.1371/journal.pmed.1000097.
M. J. Page, et al., "The PRISMA 2020 statement: An updated guideline for reporting systematic reviews," BMJ, vol. 372, n71, 2021, doi: 10.1136/bmj.n71.
A. Liberati, et al., "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions," BMJ, vol. 339, b2700, 2009, doi: 10.1136/bmj.b2700.
A. P. Siddaway, et al., "How to do a systematic review: A best practice guide for conducting and reporting narrative reviews, meta-analyses, and meta-syntheses," Br. J. Psychol., vol. 110, no. 1, pp. 5–23, 2019, doi: 10.1111/bjop.12266.
A. C. Tricco, et al., "PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation," Ann. Intern. Med., vol. 169, no. 7, pp. 467–473, 2018, doi: 10.7326/M18-0850.
A. M. Methley, S. Campbell, C. Chew-Graham, R. McNally, and S. Cheraghi-Sohi, "PICO, PICOS and SPIDER: A comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews," BMC Health Serv. Res., vol. 14, p. 579, 2014, doi: 10.1186/s12913-014-0579-0.
S. Jo, S. Kim, D. H. Shin, and M. S. Kim, "Inhibition of SARS-CoV-2 main protease by flavonoids: Molecular docking and in vitro study," Int. J. Biol. Macromol., vol. 164, pp. 471–479, 2020, doi: 10.1016/j.ijbiomac.2020.07.132.
T. T. Nguyen, et al., "Flavonoid-mediated inhibition of SARS-CoV-2 protease: An in silico analysis," ChemRxiv, 2020, doi: 10.26434/chemrxiv.12029523.
D. Bhowmik, et al., "Herbal antiviral agents and their challenges," Phytomedicine, vol. 85, p. 153343, 2021, doi: 10.1016/j.phymed.2020.153343.
A. Khalil, et al., "Quercetin as an emerging therapeutic natural product for the treatment and prevention of COVID-19," Front. Immunol., vol. 11, p. 586171, 2020, doi: 10.3389/fimmu.2020.586171.
A. Saeedi-Boroujeni and M. R. Mahmoudian-Sani, "Anti-inflammatory potential of curcumin: a review on its effects in the management of cytokine storm and beyond," Phytother. Res., vol. 35, no. 11, pp. 6545–6555, 2021, doi: 10.1002/ptr.7203.
U.S. Food and Drug Administration, "GRAS Notices," 2022. [Online]. Available: https://www.fda.gov/food/generally-recognized-safe-gras/gras-notification-program
C. Y.-C. Chen, et al., "Luteolin's antiviral effect: In silico evaluation," J. Biomol. Struct. Dyn., 2020, doi: 10.1080/07391102.2020.1777862.
L. Zhang, et al., "Kaempferol as potential antiviral agent against dengue," Virus Res., vol. 305, p. 198539, 2021, doi: 10.1016/j.virusres.2021.198539.
A. J. Siddiqui, et al., "Andrographolide as SARS-CoV-2 inhibitor: Docking study," J. Biomol. Struct. Dyn., 2020, doi: 10.1080/07391102.2020.1775125.
M. T. Qamar, et al., "Structural basis of SARS-CoV-2 inhibition by natural compounds," J. Biomol. Struct. Dyn., 2021, doi: 10.1080/07391102.2020.1758791.
R. Chandra, et al., "Epigallocatechin antiviral action against COVID-19," Phytother. Res., 2020, doi: 10.1002/ptr.6738.
Y. Li, et al., "Apigenin inhibits HIV replication in silico," Comput. Biol. Chem., vol. 89, p. 107377, 2020, doi: 10.1016/j.compbiolchem.2020.107377.
B. Salehi, et al., "Resveratrol in COVID-19 treatment," Int. J. Mol. Sci., vol. 21, no. 21, p. 7369, 2020, doi: 10.3390/ijms21217369.
S. Khaerunnisa, et al., "Potential inhibitor of COVID-19 main protease from flavonoids," J. Biomol. Struct. Dyn., 2020, doi: 10.1080/07391102.2020.1751300.
Y. B. Ryu, et al., "Eugenol inhibits coronavirus replication," Bioorg. Med. Chem., vol. 29, no. 1, p. 115859, 2021, doi: 10.1016/j.bmc.2020.115859.
C. Wu, et al., "Natural flavonoids as Mpro inhibitors of SARS-CoV," Acta Pharm. Sin. B, vol. 10, no. 5, pp. 766–788, 2020, doi: 10.1016/j.apsb.2020.02.008.
R. Y. Utomo, et al., "Berberine as COVID-19 therapy," Bioinform. Biol. Insights, vol. 14, p. 1177932220939226, 2020, doi: 10.1177/1177932220939226.
W. Dai, et al., "Amentoflavone: Potential dual target COVID-19 drug," Phytother. Res., vol. 34, no. 12, pp. 3181–3189, 2020, doi: 10.1002/ptr.6789.
A. A. Elfiky, "Thymoquinone inhibits MERS-CoV via RNA polymerase docking," J. Biomol. Struct. Dyn., vol. 38, no. 12, pp. 4150–4160, 2020, doi: 10.1080/07391102.2020.1761883.
C. Liu, et al., "Genistein inhibits SARS-CoV-2 replication," J. Med. Virol., vol. 93, no. 2, pp. 755–761, 2021, doi: 10.1002/jmv.26242.
J. S. Mani, et al., "Catechin: Broad antiviral compound," Phytother. Res., vol. 35, no. 6, pp. 3193–3203, 2021, doi: 10.1002/ptr.6978.
A. Alam, et al., "Antiviral role of naringenin: An overview," J. Food Biochem., vol. 44, no. 11, e13414, 2020, doi: 10.1111/jfbc.13414.
R. Ghosh, et al., "Astaxanthin: A potential antiviral and immune booster," Mar. Drugs, vol. 19, no. 6, p. 280, 2021, doi: 10.3390/md19060280.
H. J. Choi, et al., "Betulinic acid and SARS-CoV inhibition," Virus Res., vol. 296, p. 198345, 2021, doi: 10.1016/j.virusres.2021.198345.
T. T. Yao, et al., "Fucoidan inhibits SARS-CoV-2 replication," Carbohydr. Polym., vol. 248, p. 116802, 2020, doi: 10.1016/j.carbpol.2020.116802.
P. Shree, et al., "Diosmin binds to Mpro of SARS-CoV-2: In silico," J. Biomol. Struct. Dyn., vol. 39, no. 13, pp. 5124–5135, 2021, doi: 10.1080/07391102.2020.1775703.
A. Dwivedy, et al., "Limonene for viral inhibition: Docking study," J. Mol. Struct., vol. 1224, p. 129178, 2021, doi: 10.1016/j.molstruc.2020.129178.
K. L. Huang, et al., "Caffeic acid exhibits anti-SARS-CoV-2 activity," Antiviral Res., vol. 181, p. 104878, 2020, doi: 10.1016/j.antiviral.2020.104878.
T. E. Tallei, et al., "Chrysin inhibits SARS-CoV-2 proteins," J. Biomol. Struct. Dyn., 2021, doi: 10.1080/07391102.2020.1762741.
D. Kumar, et al., "Licochalcone A: SARS-CoV-2 main protease inhibitor," J. Biomol. Struct. Dyn., vol. 39, no. 13, pp. 5124–5135, 2021, doi: 10.1080/07391102.2020.1775703.
N. Rahman, et al., "Silibinin targets HCV replication: In vitro study," Antiviral Res., vol. 179, p. 104811, 2020, doi: 10.1016/j.antiviral.2020.104811.
Author Biography
Welly Anggraini, Faculty of Science and Technology, Universitas Islam Negeri Raden Intan Lampung
License
Copyright (c) 2025 Welly Anggraini
This work is licensed under a Creative Commons Attribution 4.0 International License.
The following terms apply to authors who publish in this journal:
1. Authors retain copyright and grant the journal first publication rights, with the work simultaneously licensed under a Creative Commons Attribution License 4.0 International License (CC-BY License) that allows others to share the work with an acknowledgment of the work's authorship and first publication in this journal.
2. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., posting it to an institutional repository or publishing it in a book), acknowledging its initial publication in this journal.
3. Before and during the submission process, authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website), as this can lead to productive exchanges as well as earlier and greater citation of published work (See The Effect of Open Access).
